Literature DB >> 17920901

Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson's disease.

D E Redmond1, A Vinuela, J H Kordower, O Isacson.   

Abstract

Surgeries involving transplantation of fetal dopamine (DA) neurons into the caudate-putamen of patients with Parkinson's disease (PD) have been performed in various clinical trials to examine a potential restoration of motor function. The absence of studies in non-human primates to define the best transplantation protocols have lead to the use of a broad variety of techniques that potentially could have a major impact on the clinical outcome. The effects of using different cell and tissue preparation, and surgical targets, remain unknown. For this purpose, 20 St. Kitts African Green Monkeys (AFG) rendered parkinsonian by i.m. injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were balanced into 4 groups and unilaterally grafted in the (a) caudate or (b) putamen with fetal ventral mesencephalic (VM) tissue as (c) solid pieces or as a (d) cell suspension. By 9 months post-transplantation all animals showed significant and similar behavioral improvement as determined by a UPDRS based PD scale. Postmortem analyses showed that VM transplants survived in all animals. They were located in both surgical target sites, producing a broad DA reinnervation of the targeted nuclei that could also extend to the non-grafted nucleus on the ipsilateral side. Although no differences between groups were found in survival of DA neurons or degree of DA reinnervation, there was a significant correlation between striatal reinnervation and behavioral recovery only in animals transplanted in the putamen surgical target. Additionally, there was in general a stronger glial reaction to solid grafts than to cell suspensions. These studies provide data for the optimal time course, cell preparation and surgical targets for systematic examinations of both potential benefits and side effects of dopamine neuron cell transplantation in primate models of PD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17920901      PMCID: PMC2174366          DOI: 10.1016/j.nbd.2007.08.008

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  57 in total

1.  Specific axon guidance factors persist in the adult brain as demonstrated by pig neuroblasts transplanted to the rat.

Authors:  O Isacson; T W Deacon
Journal:  Neuroscience       Date:  1996-12       Impact factor: 3.590

2.  Regression of parkinsonian fetal ventral mesencephalon grafts upon withdrawal of cyclosporine A immunosuppression. The CPH Neural Transplantation Group.

Authors:  J J Lopez-Lozano; G Bravo; B Brera; J Dargallo; J Salmean; J Uria; J Insausti; R Martinez; P Sanchez; C de la Torre; R Moreno
Journal:  Transplant Proc       Date:  1997 Feb-Mar       Impact factor: 1.066

Review 3.  The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety.

Authors:  S Przedborski; V Jackson-Lewis; A B Naini; M Jakowec; G Petzinger; R Miller; M Akram
Journal:  J Neurochem       Date:  2001-03       Impact factor: 5.372

4.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease.

Authors:  C R Freed; P E Greene; R E Breeze; W Y Tsai; W DuMouchel; R Kao; S Dillon; H Winfield; S Culver; J Q Trojanowski; D Eidelberg; S Fahn
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

5.  Long-term improvement in patients with severe Parkinson's disease after implantation of fetal ventral mesencephalic tissue in a cavity of the caudate nucleus: 5-year follow up in 10 patients. Clinica Puerta de Hierro Neural Transplantation Group.

Authors:  J J López-Lozano; G Bravo; B Brera; I Millán; J Dargallo; J Salmeán; J Uría; J Insausti
Journal:  J Neurosurg       Date:  1997-06       Impact factor: 5.115

6.  Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach.

Authors:  G L Defer; C Geny; F Ricolfi; G Fenelon; J C Monfort; P Remy; G Villafane; R Jeny; Y Samson; Y Keravel; A Gaston; J D Degos; M Peschanski; P Cesaro; J P Nguyen
Journal:  Brain       Date:  1996-02       Impact factor: 13.501

Review 7.  Dopaminergic transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery.

Authors:  J H Kordower; C G Goetz; T B Freeman; C W Olanow
Journal:  Exp Neurol       Date:  1997-03       Impact factor: 5.330

8.  Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies.

Authors:  J H Kordower; J M Rosenstein; T J Collier; M A Burke; E Y Chen; J M Li; L Martel; A E Levey; E J Mufson; T B Freeman; C W Olanow
Journal:  J Comp Neurol       Date:  1996-06-24       Impact factor: 3.215

9.  Xenotransplantation of porcine fetal ventral mesencephalon in a rat model of Parkinson's disease: functional recovery and graft morphology.

Authors:  W R Galpern; L H Burns; T W Deacon; J Dinsmore; O Isacson
Journal:  Exp Neurol       Date:  1996-07       Impact factor: 5.330

10.  Differential dissection of the rat E16 ventral mesencephalon and survival and reinnervation of the 6-OHDA-lesioned striatum by a subset of aldehyde dehydrogenase-positive TH neurons.

Authors:  N S Haque; C J LeBlanc; O Isacson
Journal:  Cell Transplant       Date:  1997 May-Jun       Impact factor: 4.139

View more
  23 in total

Review 1.  Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects.

Authors:  Kai-C Sonntag; Bin Song; Nayeon Lee; Jin Hyuk Jung; Young Cha; Pierre Leblanc; Carolyn Neff; Sek Won Kong; Bob S Carter; Jeffrey Schweitzer; Kwang-Soo Kim
Journal:  Prog Neurobiol       Date:  2018-04-11       Impact factor: 11.685

Review 2.  Lack of functional relevance of isolated cell damage in transplants of Parkinson's disease patients.

Authors:  Oliver Cooper; Arnar Astradsson; Penny Hallett; Harold Robertson; Ivar Mendez; Ole Isacson
Journal:  J Neurol       Date:  2009-08       Impact factor: 4.849

3.  Columnar Injection for Intracerebral Cell Therapy.

Authors:  Jeffrey S Schweitzer; Bin Song; Pierre R Leblanc; Melissa Feitosa; Bob S Carter; Kwang-Soo Kim
Journal:  Oper Neurosurg (Hagerstown)       Date:  2020-03-01       Impact factor: 2.703

4.  Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease.

Authors:  Penelope J Hallett; Michela Deleidi; Arnar Astradsson; Gaynor A Smith; Oliver Cooper; Teresia M Osborn; Maria Sundberg; Michele A Moore; Eduardo Perez-Torres; Anna-Liisa Brownell; James M Schumacher; Roger D Spealman; Ole Isacson
Journal:  Cell Stem Cell       Date:  2015-02-26       Impact factor: 24.633

Review 5.  Functions of the nigrostriatal dopaminergic synapse and the use of neurotransplantation in Parkinson's disease.

Authors:  Alex Tsui; Ole Isacson
Journal:  J Neurol       Date:  2011-05-05       Impact factor: 4.849

Review 6.  Pluripotent stem cells in regenerative medicine: challenges and recent progress.

Authors:  Viviane Tabar; Lorenz Studer
Journal:  Nat Rev Genet       Date:  2014-02       Impact factor: 53.242

7.  Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model.

Authors:  Tetsuhiro Kikuchi; Asuka Morizane; Daisuke Doi; Hiroaki Magotani; Hirotaka Onoe; Takuya Hayashi; Hiroshi Mizuma; Sayuki Takara; Ryosuke Takahashi; Haruhisa Inoue; Satoshi Morita; Michio Yamamoto; Keisuke Okita; Masato Nakagawa; Malin Parmar; Jun Takahashi
Journal:  Nature       Date:  2017-08-30       Impact factor: 49.962

8.  Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration.

Authors:  F Cicchetti; S Saporta; R A Hauser; M Parent; M Saint-Pierre; P R Sanberg; X J Li; J R Parker; Y Chu; E J Mufson; J H Kordower; T B Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-20       Impact factor: 11.205

Review 9.  Cell-based therapies for Parkinson's disease: past, present, and future.

Authors:  Kathleen M Fitzpatrick; James Raschke; Marina E Emborg
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

10.  Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease.

Authors:  A Vinuela; P J Hallett; C Reske-Nielsen; M Patterson; T D Sotnikova; M G Caron; R R Gainetdinov; O Isacson
Journal:  Brain       Date:  2008-11-06       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.